Table 1.

Registered clinical trials of ocular GVHD (from January 2018 to September 2022).

Interventions	Agent	Pts	Phase	Status	Institutions	Locations	Trial number
Drug	Cyclosporine vs. tacrolimus	89	Phase 4	Completed	Peking University Third Hospital	Beijing, China	NCT05294666
	Cyclosporine ophthalmic (Ikervis)	40	Phase 4	Recruiting	Singapore Eye Research Institute	Singapore, Singapore	NCT04636918
	Brimonidine tartrate	59	Phase 3	Terminated	Mayo Clinic Phoenix, Arizona	United States	NCT03591874
	Vigamox	30	Phase 2	Recruiting	Washington University School of Medicine Saint Louis	Missouri, United States	NCT04204122
	Pro-ocular™ topical gel 1%	38	Phase 2	Recruiting	Boston Sight Needham	Massachusetts, United States	NCT04769648
	Intravenous immune globulin (IVIG)	27	Phase 1	Completed	Illinois Eye and Ear Infirmary	Chicago, Illinois, United States	NCT03992482
	Lifitegrast 5% ophthalmic solution	30	Early Phase 1	Recruiting	Richard W Yee, MD PLLC Bellaire	Texas, United States	NCT04792580
Biological	UMSC-derived exosomes	27	Phase 1	Recruiting	Zhongshan Ophthalmic Center Guangzhou	Guangdong, China	NCT04213248
	Allogeneic platelet lysate eye drops	30	Phase 2	Recruiting	First Pavlov State Medical University of Saint Petersburg	Saint Petersburg, Russian Federation	NCT05311514
	Amniotic fluid eye drops (AFEDs)	15	Phase 1	Recruiting	University of Utah Huntsman Cancer Institute	Salt Lake City, Utah, United States	NCT03298815
	CAM-101 10%	64	Phase 1	Completed	Byers Eye Institute of Stanford University	Palo Alto, California, United States	NCT03414645
Device	Tangible Boost	50	Not Applicable	Recruiting	Boston Sight Needham	Massachusetts, United States	NCT04313725

UMSC, umbilical mesenchymal stem cell, CAM-101 10, topical fibrinogen-depleted human platelet lysate in patients.